Trial Details

Not Recruiting
Basic Information
Clinical ID c2120
Identifier ACTRN12623001337662
Trial Title Concentrations of Thioguanine and its metabolite 6TGN in Blood and Rectal Tissue Samples in Patients with Refractory Ulcerative Proctitis Administered Thioguanine by Suppository
Trial URL Visit Original Page
Study Information
Study Results

No results available

Conditions inflammatory Bowel Disease; inflammatory Bowel Disease;Oral and Gastrointestinal - Inflammatory bowel disease
Interventions Administration of thioguanine by suppository once daily, 5mg or 20mg as determined by computer randomisation, rectally for 29 days. Adherence monitored by product return, and pharmacokinetics on day 1 and day 29.
Participant Information
Sponsor Douglas Pharmaceuticals
City -
Country/Region New Zealand
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, ELDER, OLDER_ADULT
Study Design
Study Type Interventional
Phase PHASE1
Time Information
Start Date 2025-04-24
Primary Completion Date -
Completion Date -